Loading...
•
Sep 30, 2021
Cibus Q3 2021 Earnings Report
Calyxt announced financial results for the third quarter ended September 30, 2021.
Key Takeaways
Calyxt reported a revenue of $7.8 million, a gross profit of negative $0.5 million, and a net loss of $7.3 million for Q3 2021. The company also launched a new strategic direction focusing on plant-based synthetic biology solutions and commissioned its first pilot BioFactory.
Launched a new strategic initiative focusing on engineering synthetic biology solutions for a diversified customer base.
Commissioned the first pilot BioFactory, expected to be online by the end of 2021.
Appointed IBM’s Global Chief Artificial Intelligence Officer, Dr. Seth Dobrin, to Calyxt’s Scientific Advisory Board.
Launched a $50.0 million at-the-market (ATM) share issuance program, raising $3.7 million in proceeds as of the report date.
Forward Guidance
No specific forward guidance was provided in the report. The company is focusing on its new strategic direction and the development of its PlantSpring technology platform and BioFactory production system.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...